506927747 10/18/2021

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6974584

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date	
BRADLEY P. MORGAN	10/07/2021	
CHIHYUAN CHUANG	10/07/2021	

RECEIVING PARTY DATA

Name:	CYTOKINETICS, INC.		
Street Address:	280 EAST GRAND AVENUE		
City:	SOUTH SAN FRANCISCO		
State/Country:	CALIFORNIA		
Postal Code:	94080		

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	17255336

CORRESPONDENCE DATA

Fax Number: (650)494-0792

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6508134058

Email: earreola@mofo.com
Correspondent Name: QIWEN ZHONG

Address Line 1: MORRISON & FOERSTER
Address Line 2: 755 PAGE MILL ROAD

Address Line 4: PALO ALTO, CALIFORNIA 94304

ATTORNEY DOCKET NUMBER:	49892-20177.00
NAME OF SUBMITTER:	QIWEN ZHONG
SIGNATURE:	/QIWEN ZHONG/
DATE SIGNED:	10/18/2021

Total Attachments: 2

source=49892-20177_00_Assignment#page1.tif source=49892-20177_00_Assignment#page2.tif

PATENT 506927747 REEL: 057823 FRAME: 0687

Attorney Docket No.: 49892-20177.00 Client Reference No.: CK 1505 US

ASSIGNMENT

This assignment is by:

Bradley P. Morgan
 5948 Monzal Avenue
 Oakland, California 94611
 United States of America

Chihyuan Chuang
460 Bayview Avenue
Millbrae, California 91030
United States of America

(each referred to in this Assignment as "Assignor"), whose residence or mailing address information is listed above.

This Assignment is to:

Assignee: Cytokinetics, Inc.
Address: 280 East Grand Avenue

South San Francisco, California 94080

United States of America

A juristic entity duly organized under and pursuant to the laws of: Delaware

(referred to in this Assignment as "Assignee"), which desires to acquire the entire right, title and interest in, to and under the patent application identified below and the inventions covered thereby.

Assignor invented certain new and useful inventions in:

CARDIAC SARCOMERE INHIBITORS

which are set forth in:

Serial No.: 17/255,336 Filing Date: June 25, 2019 (Int'l)

(which identifying information may be added after execution)

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement,

1. Assignor hereby sells, assigns, transfers and sets over, to Assignee, its successors, legal representatives and assigns, Assignor's entire right, title and interest in and to the above-mentioned inventions, application for letters patent, any and all non-provisionals, divisions, continuations, and continuations-in-part claiming priority thereto or the benefit thereof, substitutions of said applications, and any and all letters patent or patents in the United States of America and all foreign countries or jurisdictions which may be granted therefor and thereon, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding, and any and all extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover damages for past, present and future infringement, and any and all rights to claim priority to said application and any and all applications claiming priority thereto or based on said inventions), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.

1

Attorney Docket No.: 49892-20177.00 Client Reference No.: CK 1505 US

2. Assignor represents, warrants and covenants (a) that, at the time of execution and delivery of this agreement, Assignor is the sole and lawful owner of Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said application for letters patent, and that the same are unencumbered and that Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth in this agreement, or (b) that Assignor solely and lawfully owned Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said application for letters patent, and that the same were unencumbered and that Assignor previously sold, assigned, transferred and set over, to Assignee, its successors, legal representatives and assigns, or to a predecessor in interest of Assignee, Assignor's entire right, title and interest in and to said inventions and said applications for letters patent.

- 3. Assignor shall promptly sign, execute, and deliver to Assignee all papers, instruments, affidavits, and documents, take all lawful oaths, and do all acts necessary, required or useful for the procurement, maintenance, enforcement, defense or otherwise to secure title thereto to the Assignee, at the sole cost and expense of Assignee, its successors, legal representatives and assigns, in each case including, without limitation, arising from or relating to (a) said inventions, or said application for letters patent; (b) any non-provisional, division, continuation, or continuation-in-part claiming priority thereto or the benefit thereof, or any substitution of any such application, or (c) any letters patent or patents for said inventions in any country or jurisdiction, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination, or other post-grant proceeding. For purposes of this paragraph, "procurement, maintenance, enforcement, defense" shall include, without limitation, any preparation, prosecution, pregrant proceeding, and post-grant proceeding, whether before a patent office or other administrative body or judicial body with jurisdiction therefor.
- 4. Assignor hereby authorizes and requests the Commissioner for Patents in the United States to issue the above mentioned letters patents of the United States and any reissue, reexamination, review, or extension thereof to and in the name of Assignee as the assignee of said inventions and the letters patents to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.
- 5. Assignor hereby grants attorneys, all of Morrison & Foerster LLP (or as needed attorneys of the applicable country appointed and authorized by Morrison & Foerster LLP), the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office or any foreign patent issuing authority for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known.
- 6. This assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

<u>ASSIGN</u>	OR(s):		DocuSigned by:		
Date:	10/7/2021	Signature:	985D38A145B1468		
Date:	10/7/2021	_ Signature:	Bradley P. Morgan DocuSigned by: / Lulyuan Chuang Chihyuan Chuang 470BE54D8CAF4E9		
ASSIGN Date:	I <u>EE:</u> 10/7/2021 	Signature:	Name Fady Mail TK! Title: Executive Vice President, Resea Company: Cytokinetics, Inc.	/ rch and De	evelopment

2